Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, announced Genedata Chromatics® , a unique vendor-agnostic software platform for managing and analyzing chromatography data across studies. Developed in collaboration with Genmab, a global leader in the development of next-generation therapeutic antibodies, Genedata Chromatics enables biopharma organizations to overcome chromatography data processing challenges. The platform consolidates data from multiple instruments and experiments providing a single source of truth for faster decision-making and biotherapeutic development. For this collaborative development project, Genedata and Genmab won the Bio-IT World 2025 Innovative Practices award.
Chromatography is a pillar of drug development enabling the separation, identification, and quantification of various components of therapeutic candidates to assess their quality and developability. Yet, using chromatography data to drive decisions has been challenging and inefficient due to the fragmented, outdated software landscape as well as the extensive manual steps required for data consolidation and upload to a central data repository. With Genedata Chromatics, scientists can easily analyze chromatography data combined with automatically retrieved sample metadata for efficient secondary analysis across experiments. Using Genedata Chromatics, scientists can easily report results to team members or partner groups enhancing access to data and results for collaboration.
“When creating antibody panels, we implement several RNA and DNA quality control steps to ensure fast and efficient workflows. Previously, using different data acquisition platforms — each providing proprietary QC metrics — made it challenging to compare and report data to a central repository. The newly developed Chromatics solution has solved this by enabling automated, vendor-agnostic data processing, analysis, and reporting capabilities,” said Esther van Buren, Ph.D., Expert at Genmab. “Streamlining our workflows, the solution also allows us to incorporate large sets of RNA and DNA electrophoresis data into our total antibody panel generation data review process, which gives us a more comprehensive and efficient evaluation.”
Also Read: Parse Biosciences Partners with Japanese Distributor, SCRUM Inc.
As an open platform, Genedata Chromatics integrates into existing IT infrastructure, ensuring smooth data exchange and traceability. It gathers data from applications and instruments for analytical assessment, standardizes data processing, and enhances data quality to create comparable, FAIR data. Genedata Chromatics significantly accelerates the processing of many samples in both research and development, saving time and reducing costs. At Genmab, scientists have cut data processing time from 4-8 hours per week to just 30 minutes. The improved data accessibility, combined with automated data analysis, enables deeper insights and faster decision-making, speeding up the development of biomolecules.
“Genmab seeks to integrate AI into everything we do, and we are continuously looking for ways that AI can address operational challenges,” said Rik Rademaker, Ph.D., Director at Genmab. “Our collaboration on Chromatics is aligned with that goal as the platform helps us to effectively work with vast amounts of complex data while positioning us for AI and ML initiatives — all aimed at enabling optimized decision-making and improved efficiency in bringing life-saving medicines to patients.”
“In discussions with global biopharma, we identified a critical and growing demand for efficient management and analysis of chromatography data,” said Othmar Pfannes, Ph.D., President of Genedata. “By working together with Genmab, an innovative leader in biopharma R&D, we developed a first-in-class software solution that automates and integrates complex chromatography workflows. The launch of Genedata Chromatics underscores our strategic vision to expand the Genedata Biopharma Platform to support the latest advances in biopharma R&D and ultimately help accelerate the development of effective treatments.”
SOURCE: PRWeb
